Aventis Allegra Once-Daily New Prescription Market Share Reaches 13%
Executive Summary
Aventis' once-daily Allegra (fexofenadine) represents approximately half of the antihistamine's total new prescription market share, Pharmaceuticals CEO Richard Markham said during an analyst meeting in London March 2.
You may also be interested in...
Claritin Supply Sufficient For Spring, Schering Says; FDA Lists GMP Problems
Schering-Plough will have a sufficient supply of Claritin for the spring allergy season, the company maintains.
Schering-Plough Clarinex NDA Approval Awaits Resolution Of GMP Problems
Schering-Plough's Clarinex (desloratadine) NDA will not be approved until the company answers FDA concerns regarding Good Manufacturing Practices compliance at a wide range of Schering operations.
Schering Desloratadine Launch Ads In U.K. Include Decongestant Claim
Schering-Plough's launch campaign for desloratadine in the U.K. includes a claim that the antihistamine has decongestant properties.